68 kDa cell wall Antibody

Shipped with Ice Packs
In Stock

Product Specs

Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
Form
Liquid
Lead Time
Made-to-order (14-16 weeks)
Synonyms
68 kDa cell wall protein antibody; Fragment antibody
Uniprot No.

Target Background

Subcellular Location
Secreted, cell wall.

Q&A

What are 68 kDa cell wall antibodies and what cellular structures do they target?

Cell wall antibodies targeting 68 kDa proteins are immunological probes that specifically bind to components of cellular structural elements. The most common 68 kDa cell wall antibodies include those targeting neurofilament light polypeptide (NEFL/NF-L) in neuronal cells, which functions in the maintenance of neuronal caliber . These antibodies can also be used to detect specific cell wall components in plant research, where they belong to the broader category of Cell Wall Probes (CWPs) . The specificity of these antibodies allows researchers to selectively detect, quantify, and visualize their target molecules without deconstructing the cell wall, enabling studies of components in their native context .

What detection methods can be used with 68 kDa cell wall antibodies?

68 kDa cell wall antibodies can be employed across multiple detection platforms with different sensitivity levels and applications:

  • Western Blot (WB): Effective for quantitative analysis of protein expression in tissue lysates (typical dilution 1/5000)

  • Immunohistochemistry (IHC-P): For localization in fixed tissue sections

  • Immunocytochemistry/Immunofluorescence (ICC/IF): For subcellular localization studies

  • Flow Cytometry (Flow Cyt): For quantitative analysis at the single-cell level

When designing experiments, it's critical to validate antibody performance for your specific application and tissue type, as cross-reactivity may occur between similar structural proteins.

What controls should be included when using 68 kDa cell wall antibodies?

A robust experimental design must incorporate appropriate controls:

  • Positive controls: Include samples known to express the target (e.g., rat brain tissue for neurofilament antibodies)

  • Negative controls: Include samples lacking the target or use isotype-matched irrelevant antibodies

  • Absorption controls: Pre-incubate antibody with purified antigen to confirm specificity

  • Secondary antibody-only controls: To detect non-specific binding of secondary detection systems

These controls help distinguish true signals from artifacts and validate the specificity of observed labeling patterns.

How can epitope characterization be performed for 68 kDa cell wall antibodies?

Precise epitope determination is crucial for understanding antibody binding properties and potential cross-reactivity. Modern approaches include:

  • High-throughput screening platforms: Enable hierarchical clustering analysis of antibody specificities

  • Chemical synthesis of pure oligosaccharides: Allows detailed characterization of epitope structures recognized by antibodies targeting carbohydrate components

  • Epitope mapping using truncated protein domains: Identifies specific binding regions, as demonstrated in studies where the adenosine triphosphatase (ATPase) domain of HSC70 was identified as the binding region for certain ligands

  • Competitive binding assays: Using defined fragments or synthetic peptides to inhibit antibody binding

These approaches have revealed, for example, that some antibodies require minimum chain lengths or specific substitution patterns for recognition, explaining their complementary labeling patterns in tissues .

What strategies can address cross-reactivity issues with 68 kDa cell wall antibodies?

Cross-reactivity remains a significant challenge with structural protein antibodies due to conserved domains across protein families. Advanced strategies to address this include:

  • Computational prediction: In silico analysis of potential cross-reactive epitopes

  • Pre-absorption experiments: Pre-incubating antibodies with related proteins

  • Knockout/knockdown validation: Using genetically modified systems lacking the target

  • Parallel labeling: Using multiple antibodies targeting different epitopes of the same protein

  • Western blot correlation: Confirming single-band specificity at the predicted molecular weight

These approaches can significantly enhance the reliability of results, particularly in complex tissue environments where multiple related structural proteins may be present.

How can 68 kDa cell wall antibodies be applied in high-throughput screening approaches?

High-throughput applications of these antibodies have transformed cell wall research through:

  • Comprehensive microarray polymer profiling (CoMPP): Using nitrocellulose-based microarrays for rapid screening of multiple samples

  • ELISA-based methods: For quantitative comparison across sample sets

  • Epitope detection chromatography (EDC): Coupling size-exclusion or anion-exchange chromatography with immunodetection to obtain structural information while identifying specific components

  • Automated image analysis workflows: For quantitative assessment of labeling patterns across tissue sections

These methods have proven valuable for characterizing cell walls across different species, analyzing biomass composition, and studying tissue-specific distribution of epitopes, dramatically increasing research throughput .

What factors affect reproducibility when working with 68 kDa cell wall antibodies?

Ensuring reproducible results requires careful consideration of several variables:

FactorImpactBest Practice
Antibody concentrationSignal-to-noise ratioTitrate for each application
Incubation conditionsBinding kineticsStandardize temperature and duration
Buffer compositionEpitope accessibilityOptimize pH and ionic strength
Sample preparationEpitope preservationStandardize fixation and processing
Detection systemSignal amplificationSelect appropriate sensitivity level
Batch variabilityData consistencyUse same lot when possible, include standards

Maintaining detailed protocols and standardizing each step of the experimental workflow are essential for generating reproducible data across experiments.

How should researchers validate novel 68 kDa cell wall antibody applications?

When adapting antibodies to new applications or tissue types, validation should include:

  • Reactivity testing: Confirm binding to target in the new application context

  • Species cross-reactivity assessment: Particularly important when working with evolutionarily conserved structural proteins

  • Correlation with alternative detection methods: Compare with other established techniques

  • Dose-response experiments: Demonstrate specificity through dilution series

  • Blocking peptide experiments: Confirm epitope specificity

For plant cell wall studies, validation may also include competing the antibody with defined oligosaccharides to confirm glycan epitope specificity .

How can researchers quantitatively analyze 68 kDa cell wall antibody binding patterns?

Quantitative analysis of binding patterns can provide insights into structural changes or expression levels:

  • Western blot densitometry: For relative quantification across samples, with normalization to loading controls

  • Fluorescence intensity measurement: For quantifying signal in microscopy applications

  • Flow cytometry analysis: For population-level quantification of binding

  • Image analysis algorithms: For spatial distribution analysis in tissue sections

What approaches can resolve contradictory results when using different 68 kDa cell wall antibodies?

When different antibodies targeting the same protein yield contradictory results, systematic troubleshooting approaches include:

  • Epitope mapping comparison: Determine if antibodies recognize different domains that may be differentially accessible

  • Post-translational modification analysis: Assess whether modifications affect epitope recognition

  • Denaturation-sensitivity testing: Evaluate whether antibodies recognize native vs. denatured conformations

  • Cross-validation with non-antibody methods: Such as mass spectrometry or genetic approaches

  • Literature-based meta-analysis: Compare with published results using the same antibodies

This systematic approach can resolve apparent contradictions and may reveal biologically relevant insights about protein structure or interactions.

How can genetic engineering enhance the utility of 68 kDa cell wall antibodies?

Genetic approaches can overcome limitations of traditional antibody applications:

  • Expression of antibody fragments in planta: As fusion proteins with small immunotags or fluorescent proteins for dynamic studies

  • Site-directed mutagenesis: To modulate antibody affinity or specificity

  • Alternative binding scaffolds: Development of aptamers or affimers targeting cell wall components

  • Nanobody development: Creating smaller, more penetrant detection tools

These approaches open new avenues for studying cell wall dynamics and microdomains with greater spatial and temporal resolution.

What emerging technologies are expanding the applications of 68 kDa cell wall antibodies?

Recent technological advances are creating new opportunities:

  • Super-resolution microscopy: Enables visualization of structural details below the diffraction limit

  • Proximity labeling techniques: Allow identification of molecular neighbors in complex structures

  • Cryo-electron microscopy: Provides structural context for antibody binding sites

  • Single-cell omics integration: Correlates antibody labeling with transcriptomic or proteomic profiles

  • Automation and robotics: Enhances reproducibility and throughput of antibody-based assays

These emerging technologies are transforming how researchers utilize antibodies in structural biology and cell biology research.

What are the current limitations of 68 kDa cell wall antibody research?

Despite their utility, several challenges remain:

  • Epitope accessibility issues: Particularly in dense structural networks

  • Limited repertoire: The need for more diverse epitope recognition

  • Batch-to-batch variability: Affecting reproducibility across studies

  • Cross-reactivity concerns: Especially for highly conserved structural domains

  • Quantification challenges: Converting binding signals to absolute quantities

Addressing these limitations requires continued development of new antibodies and complementary detection approaches.

What future developments will advance 68 kDa cell wall antibody applications?

Anticipated advances include:

  • AI-assisted epitope prediction: Improving antibody design specificity

  • Multiplexed detection systems: Allowing simultaneous visualization of multiple components

  • Engineered binding proteins: With enhanced specificity and controlled affinity

  • Integration with -omics approaches: Providing systems-level context for structural studies

  • In vivo imaging applications: Enabling real-time visualization of dynamic structural changes

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.